AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21178832 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 123
Study 21178832 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (no treatment)
Number of subjects: 123
Study 18513463 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg, 3 times daily
Number of subjects: 86
Study 18513463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day
Number of subjects: 86
Study 18513463 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg, 3 times daily + Ezetimibe 10 mg/day
Number of subjects: 86
Study 18513463 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 86
Study 16263768 — intervention group
Group type: EXPERIMENTAL
Intervention: 73% Normoxia
Number of subjects: 8
Study 16263768 — intervention group
Group type: EXPERIMENTAL
Intervention: 72% Hypoxia
Number of subjects: 8
Study 16263768 — intervention group
Group type: COMPARATOR
Intervention: 51% Normoxia
Number of subjects: 8
Study 15069431 — intervention group
Group type: EXPERIMENTAL
Intervention: PACG
Number of subjects: 230
Study 15069431 — intervention group
Group type: COMPARATOR
Intervention: POAG
Number of subjects: 230
Study 11434162 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 96
Study 11434162 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (grade II)
Number of subjects: 96
Study 11434162 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (grade III)
Number of subjects: 96
Study 11434162 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (grade I)
Number of subjects: 96
Study 11434162 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 96
Study 11434162 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 96
Study 9720838 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg twice daily zinc therapy for 3 months
Number of subjects: 100
Study 7727550 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 40
Study 7727550 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 40
Study 2902379 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlin‐Frankfurt‐Munster (BFM) 76/79 regimen
Number of subjects: 229
Study 2902379 — intervention group
Group type: EXPERIMENTAL
Intervention: New York (NY) regimen
Number of subjects: 229
Study 2902379 — intervention group
Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 229
Study 31012819 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Only (EO)
Number of subjects: 14
Study 31012819 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with Energy Replacement (ER)
Number of subjects: 14
Study 31012819 — intervention group
Group type: COMPARATOR
Intervention: No Exercise (NE)
Number of subjects: 14
Study 31852527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic surgery
Number of subjects: 106
Study 31852527 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy males)
Number of subjects: 106
Study 28576285 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 672
Study 28576285 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.5 mg/kg)
Number of subjects: 672
Study 28576285 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ketamine (1.0 mg/kg)
Number of subjects: 672
Study 26162735 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-review
Number of subjects: 202
Study 26162735 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 202
Study 23261647 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash of blue light
Number of subjects: 120
Study 23261647 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash of red light
Number of subjects: 120
Study 23261647 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash of white light
Number of subjects: 120
Study 23261647 — intervention group
Group type: COMPARATOR
Intervention: Control group (no flash of light)
Number of subjects: 120
Study 22047811 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of dexamethasone (2 mg)
Number of subjects: 24
Study 22047811 — intervention group
Group type: COMPARATOR
Intervention: Tablet formulation of dexamethasone (2 mg)
Number of subjects: 24
Study 22047811 — intervention group
Group type: COMPARATOR
Intervention: Liquid vs Tablet
Number of subjects: 24
Study 22047811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic parameter AUEC
Number of subjects: 24
Study 19957671 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 89
Study 19957671 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-drill treatment
Number of subjects: 89
Study 19957671 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment in PSCO group
Number of subjects: 89
Study 19957671 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment in NLDO group
Number of subjects: 89
Study 19957671 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-drill treatment in PSCO group
Number of subjects: 89
Study 19957671 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-drill treatment in NLDO group
Number of subjects: 89
Study 19957671 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment complications
Number of subjects: 89
Study 19957671 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-drill treatment complications
Number of subjects: 89
Study 16799342 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone extubation (group P)
Number of subjects: 105
Study 16799342 — intervention group
Group type: COMPARATOR
Intervention: Supine extubation (group S)
Number of subjects: 105
Study 16799342 — intervention group
Group type: COMPARATOR
Intervention: Supine extubation with intravenous lidocaine (group SL)
Number of subjects: 105
Study 12763210 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (Faslodex)
Number of subjects: 0
Study 12763210 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (Arimidex)
Number of subjects: 0
Study 12763210 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (Faslodex) and Anastrozole (Arimidex)
Number of subjects: 0
Study 10944136 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS involvement at diagnosis (lymphoma cells in the CSF, cranial nerve palsy)
Number of subjects: 445
Study 10944136 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS involvement at diagnosis
Number of subjects: 445
Study 10944136 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum LDH or higher modified stage
Number of subjects: 445
Study 9310014 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 28
Study 9310014 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 28
Study 8100611 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (500 mg twice daily)
Number of subjects: 993
Study 2880655 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN-beta)
Number of subjects: 11
Study 2880655 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma)
Number of subjects: 11
Study 29479645 — intervention group
Group type: EXPERIMENTAL
Intervention: Total daily sitting time
Number of subjects: 123
Study 29479645 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent breaks in sitting time
Number of subjects: 123
Study 26612114 — intervention group
Group type: EXPERIMENTAL
Intervention: White bread with baobab fruit extract (1.88%)
Number of subjects: 13
Study 26612114 — intervention group
Group type: EXPERIMENTAL
Intervention: White bread with green tea extract (0.4%)
Number of subjects: 13
Study 26612114 — intervention group
Group type: COMPARATOR
Intervention: Control white bread
Number of subjects: 13
Study 26573101 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy (n = 25)
Number of subjects: 336
Study 26573101 — intervention group
Group type: EXPERIMENTAL
Intervention: Perigee procedure (n = 76)
Number of subjects: 336
Study 26573101 — intervention group
Group type: COMPARATOR
Intervention: Women with Green type III cystocele
Number of subjects: 336
Study 23535509 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 0
Study 23535509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21374904 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail Anti-Rotation (PFNA)
Number of subjects: 107
Study 21374904 — intervention group
Group type: COMPARATOR
Intervention: Third Generation Gamma Nail (TGN)
Number of subjects: 107
Study 18087209 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (rTMS)
Number of subjects: 14
Study 18087209 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (placebo)
Number of subjects: 14
Study 15983153 — intervention group
Group type: EXPERIMENTAL
Intervention: ILMA tracheal tube (TT; for LMA‐Fastrach)
Number of subjects: 40
Study 15983153 — intervention group
Group type: COMPARATOR
Intervention: Standard PVC TT (Portex)
Number of subjects: 40
Study 14667881 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist administered from stimulation day 6
Number of subjects: 81
Study 14667881 — intervention group
Group type: COMPARATOR
Intervention: Control group (serum P <1.2 ng/mL)
Number of subjects: 81
Study 10978402 — intervention group
Group type: EXPERIMENTAL
Intervention: Target Hb of 14 g/dl
Number of subjects: 14
Study 10978402 — intervention group
Group type: COMPARATOR
Intervention: Target Hb of 10 g/dl
Number of subjects: 14
Study 8642853 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-973 at MTD of 1000 mg/m2 per course
Number of subjects: 36
Study 8642853 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-973 at doses > or = 1000 mg/m2
Number of subjects: 36
Study 8642853 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-973 therapy
Number of subjects: 36
Study 8642853 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-973
Number of subjects: 36
Study 1848289 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintered hydroxyapatite implant material
Number of subjects: 0
Study 1848289 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 0
Study 6229864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium nasal spray
Number of subjects: 30
Study 6229864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6229864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 30
Study 30879732 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cord clamping
Number of subjects: 45
Study 30879732 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 45
Study 30879732 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Number of subjects: 45
Study 29151225 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanone intake
Number of subjects: 78
Study 29151225 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavone intake
Number of subjects: 78
Study 29151225 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanidins and flavan‐3‐ols
Number of subjects: 78
Study 29151225 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanidins, flavan‐3‐ols and flavonols
Number of subjects: 78
Study 29151225 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonols
Number of subjects: 78
Study 29151225 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavan‐3‐ols intake
Number of subjects: 78
Study 26817621 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 99
Study 26817621 — intervention group
Group type: COMPARATOR
Intervention: Disulfiram
Number of subjects: 99
Study 26817621 — intervention group
Group type: COMPARATOR
Intervention: Placebo with no CM
Number of subjects: 99
Study 26817621 — intervention group
Group type: COMPARATOR
Intervention: No CM
Number of subjects: 99
Study 26817621 — intervention group
Group type: EXPERIMENTAL
Intervention: One year follow-up
Number of subjects: 99
Study 25100363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 3
Study 25100363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 22997783 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave electroacupuncture
Number of subjects: 129
Study 22997783 — intervention group
Group type: EXPERIMENTAL
Intervention: Disperse-dense wave electroacupuncture
Number of subjects: 129
Study 22997783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent wave electroacupuncture
Number of subjects: 129
Study 19837005 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Therapy (SMT)
Number of subjects: 80
Study 19837005 — intervention group
Group type: COMPARATOR
Intervention: Light Massage (LM)
Number of subjects: 80
Study 17710799 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus moxibustion combined with a psychological approach
Number of subjects: 310
Study 16249724 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany
Number of subjects: 0
Study 16249724 — intervention group
Group type: COMPARATOR
Intervention: gutta-percha/AH Plus
Number of subjects: 0
Study 12150239 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger elicitation
Number of subjects: 109
Study 12150239 — intervention group
Group type: EXPERIMENTAL
Intervention: Shame elicitation
Number of subjects: 109
Study 12150239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pride elicitation
Number of subjects: 109
Study 12150239 — intervention group
Group type: COMPARATOR
Intervention: Neutral opinion-expression task (nonemotion condition)
Number of subjects: 109
Study 11137053 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-Hz rTMS
Number of subjects: 10
Study 11137053 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS
Number of subjects: 10
Study 11137053 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 20-Hz and 1-Hz rTMS
Number of subjects: 10
Study 9337606 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in procedural justice
Number of subjects: 71
Study 9337606 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 1441734 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (3 intramuscular injections at months 0, 1, and 2)
Number of subjects: 197
Study 1441734 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (271 participants, mean age 24.2 years)
Number of subjects: 197
Study 1441734 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 197
Study 2863799 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC‐9447 (topical beta adrenergic antagonist)
Number of subjects: 17
Study 2863799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30321051 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotypic expectations from multiple perceivers
Number of subjects: 241
Study 30321051 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgments by new perceivers
Number of subjects: 241
Study 27131029 — intervention group
Group type: EXPERIMENTAL
Intervention: Subperiosteal surgical dissection
Number of subjects: 32
Study 27131029 — intervention group
Group type: COMPARATOR
Intervention: Supraperiosteal surgical dissection
Number of subjects: 32
Study 23929687 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration olfactory training (OT) for 18 weeks
Number of subjects: 144
Study 23929687 — intervention group
Group type: COMPARATOR
Intervention: Low concentration olfactory training (OT) for 18 weeks
Number of subjects: 144
Study 23929687 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration olfactory training (OT) for 18 weeks in subjects with <12 months duration of dysfunction
Number of subjects: 144
Study 23929687 — intervention group
Group type: COMPARATOR
Intervention: Low concentration olfactory training (OT) for 18 weeks in subjects with <12 months duration of dysfunction
Number of subjects: 144
Study 24032192 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm needling therapy
Number of subjects: 136
Study 24032192 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture therapy
Number of subjects: 136
Study 24032192 — intervention group
Group type: COMPARATOR
Intervention: Common acupuncture therapy
Number of subjects: 136
Study 21358250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic hip screw (DHS)
Number of subjects: 157
Study 21358250 — intervention group
Group type: COMPARATOR
Intervention: AO angled blade plate (AP)
Number of subjects: 157
Study 18543482 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal needling (AN) applied at Xiawan (Ren 10), Qihai (Ren 6), Qipang, Guanyuan (Ren 4), Qixue, Shuifen (Ren 9), Tianshu (St. 25) and Daju (St. 27), starting from the first day after operation, once every day for 5 days with needle retained for 20 min.
Number of subjects: 60
Study 18543482 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with intravenous injection of 20 mg Omeprazole once a day for 3 successive days.
Number of subjects: 60
Study 16415703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (25 mg/d for 1 week, then 50 mg/d for 15 weeks)
Number of subjects: 76
Study 16415703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 16415703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 76
Study 12790861 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-tracheal suction
Number of subjects: 47
Study 12790861 — intervention group
Group type: COMPARATOR
Intervention: Closed-tracheal suction
Number of subjects: 47
Study 10818030 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment (warfarin) after individualised decision analysis
Number of subjects: 260
Study 10818030 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision analysis
Number of subjects: 260
Study 10818030 — intervention group
Group type: COMPARATOR
Intervention: Warfarin prescription
Number of subjects: 260
Study 8867905 — intervention group
Group type: EXPERIMENTAL
Intervention: GL-METF (2.5 mg glibenclamide and 400 mg metformin)
Number of subjects: 30
Study 8867905 — intervention group
Group type: COMPARATOR
Intervention: GL-PHEN (2.5 mg glibenclamide and 25 mg phenformin)
Number of subjects: 30
Study 1502356 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain abdominal radiographs
Number of subjects: 97
Study 29366513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 50mg once daily
Number of subjects: 1232
Study 29366513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 100mg once daily
Number of subjects: 1232
Study 29366513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1232
Study 29366513 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidafenacin 0.1mg twice daily
Number of subjects: 1232
Study 27006266 — intervention group
Group type: EXPERIMENTAL
Intervention: Decremental target minute ventilation (DTMV)
Number of subjects: 52
Study 27006266 — intervention group
Group type: COMPARATOR
Intervention: Constant target minute ventilation
Number of subjects: 52
Study 24969648 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised 3% hypertonic saline (n=84)
Number of subjects: 292
Study 24969648 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised 6% hypertonic saline (n=83)
Number of subjects: 292
Study 24969648 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (n=80)
Number of subjects: 292
Study 24969648 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (3%, 6%, and 0.9% saline)
Number of subjects: 292
Study 22700039 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (GAL) 8 mg/day
Number of subjects: 12
Study 22700039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21029662 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTNFR:Fc 0.4 mg/kg, subcutaneously injected twice weekly
Number of subjects: 31
Study 21029662 — intervention group
Group type: COMPARATOR
Intervention: MTX 10 mg × m(‐2) × w(‐1)
Number of subjects: 31
Study 21029662 — intervention group
Group type: EXPERIMENTAL
Intervention: SASP 30‐50 mg × kg(‐1) × d(‐1) (for intolerance patients)
Number of subjects: 31
Study 18347619 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyelid hygiene regimen
Number of subjects: 0
Study 18347619 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotics
Number of subjects: 0
Study 18347619 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 0
Study 18347619 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics
Number of subjects: 0
Study 16450078 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene mesh
Number of subjects: 600
Study 16450078 — intervention group
Group type: COMPARATOR
Intervention: Vypro II mesh
Number of subjects: 600
Study 12856976 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 80
Study 12856976 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 80
Study 10559091 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg/d HFA-BDP
Number of subjects: 347
Study 10559091 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg/d CFC-BDP
Number of subjects: 347
Study 10559091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 8934215 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose administration (75 g)
Number of subjects: 10
Study 8934215 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1 ml)
Number of subjects: 10
Study 8934215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PST, 120 mg)
Number of subjects: 10
Study 6336781 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP/SMX + E
Number of subjects: 150
Study 6336781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 31542391 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg and Quercetin 1000 mg for 3 days
Number of subjects: 9
Study 29595449 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oxygen (3 l/min if baseline oxygen saturation ≤ 93%, 2 l/min if > 93%) for 72 hours after randomisation
Number of subjects: 8003
Study 29595449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen (same flow rates as continuous) for three consecutive nights
Number of subjects: 8003